News Archives

News Archives

Avivagen Announces Non-Dilutive Financing in Support of Increased Product Sales

Ottawa, ON /Business Wire/ October 15, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that given the recent significant ramp up in …Read More

Avivagen Announces Record Four Tonne Order from UNAHCO

Four tonne order is the largest one-time purchase in Avivagen’s history, and follows UNAHCO’s three tonne order in April of this year, a previous record order Order comprised of two separate two tonne shipments that demonstrate UNAHCO’S expanded use of OxC-betaTM throughout the region. Ottawa, ON / Business Wire/ October 13, 2020 / – Avivagen …Read More

Avivagen Receives Multiple New Orders and Joins Influential Industry Associations in Mexico

• Introductory purchase orders secured with Forrajes Tesistan and Prolea
• Membership in ANFACA and AMEPA to provide extended access to feed mills and farms throughout Mexico

Avivagen Receives 10 Tonne Purchase Order for OxC-beta Livestock from Large North American Client

Ottawa, ON /Business Wire/ September 28, 2020 / –Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce that it has received a new purchase order for …Read More

Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

Ottawa, ON /Business Wire/ September 15, 2020/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to extend …Read More

Avivagen Inc. Announces Proposed Extension of Warrants

Ottawa, ON /Business Wire/ September 9, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX …Read More